Mr David Rosenthal > Dechert LLP > New York, United States > Lawyer Profile

Dechert LLP’s global team advises leading life sciences companies in both contentious and non-contentious matters. The practice is particularly strong in IP, with figures such as New York-based first-chair attorney Katherine Helm leading in patent litigation. The team is also involved in antitrust and product liability matters, an example of the latter being its role as lead national counsel for GlaxoSmithKline in the multi-district and state-court mass tort litigation concerning allegations that Zantac causes cancer. It has also advised in matters at the increasingly significant intersection of healthcare data privacy and tech. The practice is headed by Boston-based Andrea Reid, an IP counseling and prosecution expert, and New York’s David Rosenthal, who focuses on the team’s corporate and financial transactions work. Jennifer Csik Hutchens joined the Charlotte office from Bryan Cave Leighton Paisner in January 2025, expanding the team’s regulatory expertise.

Dechert LLP’s capital markets team is active on issuer-side engagements in the financial services sector, with notable expertise when it comes to offerings by business development companies (BDCs). Harry Pangas in Washington DC has deep experience representing BDCs, registered closed-end funds, interval funds, and tender offer funds. Boston-based Thomas Friedmann has a strong track record advising issuers and investment banks on public and private securities transactions. He also advises alternative asset managers on accessing capital via BDCs and closed-end funds, among other vehicles. Stephen Leitzell in Philadelphia is noted particularly for his work in the healthcare and tech sectors. The three partners lead the group along with New York-based Anna Tomczyk, whose varied practice spans Rule 144A and Reg S offerings, among other kinds. David Rosenthal is active in the life sciences space. Washington DC’s Matthew Carter is also a key contact in the group.

Dechert LLP’s global capital markets team stands out for its work involving business development companies (BDCs). Thomas Friedmann in Boston represents both domestic and foreign issuers as well as investment banks in connection with public and private securities transactions. Philadelphia’s Stephen Leitzell is especially active in the healthcare and tech sectors. Harry Pangas in Washington DC is noted for his work for BDCs, registered closed-end funds, interval funds, and tender offer funds. The three partners lead the group along with New York-based Anna Tomczyk. David Rosenthal in New York has a strong track record advising corporations, investment banks, and venture capital firms operating in the life sciences space.

Leveraging cross-border capabilities with Caribbean and Middle Eastern jurisdictions, Dechert LLP boasts a strong track record in private placements, IPOs, and public offerings of common stock. Advising both issuers and underwriters, the team is highly knowledgeable on equity-linked and other securities offerings, with Boston-based Thomas Friedmann routinely navigating sensitive disclosure matters under the Securities Exchange Act of 1934. From Washington DC, Harry Pangas concentrates on joint ventures and other strategic transactions, in New York, David Rosenthal acts for investment banks and venture capital funds, while Philadelphia’s Stephen Leitzell stands out for his corporate governance work.

Specializing in complex private placements, spin-offs, and senior unsecured notes offerings, Dechert LLP has a strong track record of representing sovereign issuers and financial sponsors across domestic and international jurisdictions. The firm is especially active in the healthcare, finance, and manufacturing fields, with Boston-based Thomas Friedmann routinely acting on behalf of investment banks and asset managers. From Washington DC, Harry Pangas is knowledgeable in joint ventures, New York’s David Rosenthal is a venture capital expert, while in Philadelphia, Stephen Leitzell focuses on cross-border M&A.